Refractory Multiple Myeloma Market Insights: $3.4 Billion By 2030 | CAGR 4.7%

The Global Refractory Multiple Myeloma Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 3.4 billion by 2030. The Global Refractory Multiple Myeloma Market is expected to exhibit a CAGR of 4.7% during the forecast period 2024-2031.

The Refractory Multiple Myeloma Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with the knowledge needed to make strategic decisions and maintain a competitive advantage. Utilizing a blend of qualitative and quantitative research methodologies, the firm delivers in-depth reports that support clients in understanding complex market dynamics, fostering strategic development, and capturing new opportunities in today's rapidly changing global environment.

Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/refractory-multiple-myeloma-market?kb

Evolving Market Forces and Opportunities:

Refractory multiple myeloma is a form of blood cancer that no longer responds to standard treatments, making it challenging to control and requiring alternative therapies. It is characterized by persistent or progressive disease despite prior therapies.

Key Industry Players Driving the Refractory Multiple Myeloma Market:

Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited and Genentech, Inc. among others.

Industry Development:

1. On June 6, 2023, Janssen Pharmaceutical, a division of Johnson & Johnson, announced the submission of a supplementary biologics license application (sBLA) to the U.S. FDA. The application seeks approval for an additional indication of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to treat adult patients with refractory or relapsed multiple myeloma who have received at least one prior therapy.

2. On April 17, 2023, the KarMMa-3 study evaluated the treatment of adult patients with relapsed or refractory multiple myeloma who had been treated with an immunomodulatory drug, an anti-CD38 monoclonal antibody, and a proteasome inhibitor.

3. On June 5, 2023, Kite, a Gilead Company, announced detailed results from the landmark Phase 3 ZUMA-7 study, which compared Yescarta (axicabtagene ciloleucel) CAR T-cell therapy against the traditional standard of care (SOC) as a first-line treatment for patients with refractory or relapsed large B-cell lymphoma (R/R LBCL).

Research Methodology:

Both primary and secondary data sources have been used in the global Refractory Multiple Myeloma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/refractory-multiple-myeloma-market?kb

Segment Covered in the Refractory Multiple Myeloma Market:

By Drug Type: Proteasome Inhibitor, Immunomodulators, Anti-CD38 Monoclonal Antibody, Others

By Route of Administration: Oral, Parenteral

By Product Type: Tablet, Capsule, Solution, Suspension

By End User: Hospitals, Surgical Centres/ Clinics, Others

Regional Overview for Refractory Multiple Myeloma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/refractory-multiple-myeloma-market?kb

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Refractory Multiple Myeloma market?

➠ Who are the leading manufacturers in the global Refractory Multiple Myeloma industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Refractory Multiple Myeloma industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Refractory Multiple Myeloma market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.